S

NOV 13 2000 W

PTO/SB/21 (07-06) Approved for use through 09/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ne Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/812,298 TRANSMITTAL Filing Date March 29, 2004 First Named Inventor **FORM** Guitton Art Unit Not yet assigned **Examiner Name** Not yet assigned (to be used for all correspondence after initial filing) Attorney Docket Number AUR-2001US01 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer **Extension of Time Request** below): Request for Refund **Express Abandonment Request** COPY - Refs D3, D4, D5, D8, D9, D10 and Return Receipt Postcard. CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) The Commissioner is hereby authorized to charge any fee deficiencies or credit any Reply to Missing Parts/ overpayments associated with this submission to the PIERCE ATWOOD LLP Deposit Account Incomplete Application No. 50-0282. Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name PIERCE ATWOOD LLP Signature Printed name KEVIN M. FARRELL Date Reg. No. 35,505 uCERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with

## I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature DEBRA J. KELLOM Date Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Guitton et al. Application No.: 10/812,298

Filed: March 29, 2004 Examiner: Not yet assigned Art Unit: Not yet assigned

Title: METHODS FOR THE TREATMENT OF TINNITUS INDUCED BY COCHLEAR

EXCITOTOXICITY
Docket No.: AUR-2001US01

## **CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with The United States Postal Service as First Class Mail in an envelope Addressed to Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 117/2506

PIERCE ATWOOD

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

[X] under 37 CFR 1.97(b), or

(Filed within three months of filing national application; within three months of date of entry of national stage of international application; or before mailing date of first office action on the merits; whichever occurs last)

- [] under 37 CFR 1.97(c) together with either:
  - [] a Certification under 37 CFR 1.97(e), or
  - [] a \$180.00 fee set forth in 37 CFR 1.17(p), or

(Filed after the CFR 1.97(b) time period, but before final action or notice of allowance)

The undersigned hereby certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement.



[]	under 37 CFR 1.97(d) together with: [] a Certification under 37 CFR 1.97(e), and [] a fee set forth in 37 CFR 1.17(p).						
	(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)						
Method of Fee Payment:							
[]	Enclosed is a check in the amount of \$						
[]	Please charge Deposit Account 500282 in the amount of \$						
[]	Two duplicate copies of this Statement are enclosed.						
[X]	Please charge any deficiency in fees and credit any overpayment to Deposit Account 500282.						
Enclos	Enclosed herewith is form PTO-1449:						
[]	Copies of the cited references are enclosed.						
[X]	Copies of cited references are enclosed except those of record in prior applications, U.S. Serial Nos., and references that are not required to be submitted under Rule 98.						
Concise Explanation Requirements:							
[X]	The "c	concise explanation" requirement under C.F.R. 1.98(a)(3) is satisfied by:					
	[X]	the explanation provided on the attached sh	neet.				
	[] the explanation provided in the Specification.						
	It is requested that the information disclosed herein be made of record in this application						
			Respectfully submitted,				
			Mendenal				
			Kevin M. Farrell Attorney for Applicants Registration No. 35,505 (603) 433-6300				
Portsmouth, NH Dated: 10730/04							

P0109753.DOC

## Concise Explanation under C.F.R. 1.98(a)(3)

Regarding cited reference D4 (Puel et al.2002), an English translation of this reference is not readily available to any individuals designated in § 1.56(c).

In the Opinion of an International Search Report, reference D4 was disclosed as a document of particular relevance in view of which the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone. The Opinion states that D4 discloses "the use of various NMDA receptor antagonists for treating tinnitus..." on page 1, lines 1-16; page 3, line 15 – page 4, line 13; page 12, lines 8 – 16; page 14, line 5 – page 16, line 10. The Opinion further states that "NMDA antagonists have been already described in the prior art as being useful in the treatment of tinnitus" and that the present invention appears to be an obvious alternative over reference D4.

PTO/SB/08B (07-06) Approved for use through 09/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known or form 1449/PTO Bra madel **Application Number** 10/812,298 **INFORMATION DISCLOSURE Filing Date** March 29, 2004 STATEMENT BY APPLICANT **First Named Inventor** Matthieu Guitton **Art Unit** Not yet assigned (Use as many sheets as necessary) **Examiner Name** 

Attorney Docket Number

Sheet

1

of 1

Not yet assigned

AUR-2001US01

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
	D3	M.J. GUITTON, ET AL., Cochlear NMDA receptors and tinnitus, Audiological Medicine 2(1): 3-7 (Mar. 2004).	
	D4	J. PUEL ET AL., Treatment of tinnitus. New perspectives!, Presse Medicale 31(24): 1137-1143 (Jul. 2002).	
	D5	J.J. SIMPSON ET AL., Recent advances in the pharmacological treatment of tinnitus, Trends in Pharmacological Sciences 20(1): 12-18 (Jan. 1999).	
	D8	M. J. GUITTON ET AL., New pharmacological strategies to restore hearing and treat tinnitus, ACTA OTO-Laryngologica 124(4): 411-15 (May 2004).	
	D9	J.A. KALTENBACH ET AL., Plasticity of spontaneous neural activity in the dorsal cochlear nucleus after intense sound exposure, Hearing Res 147 (1-2): 282-292 (Sept. 2000).	
	D10	M. KENMOCHI ET AL., Salicylate and quinine affect the central nervous system, Hearing Res 113(1-2): 110-116 (1997).	
_			

Examiner	Date	
Signature	 Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.